introduct
ii
picornavirus
enteroand
rhinovirus
iii
alphaand
flavivirus
yellow
fever
dengu
west
nile
iv
hepacivirus
hcv
v
coronavirus
sar
vi
orthomyxovirus
influenza
b
vii
paramyxovirus
parainfluenza
measl
mump
rsv
hmpv
nipah
viii
arena
bunya
rhabdoand
filovirus
ix
reovirus
x
conclus
refer
abstract
compound
formal
licens
clinic
use
antivir
drug
half
use
treatment
hiv
infect
other
approv
therapi
herpesviru
hsv
vzv
cmv
hepadnaviru
hbv
hepaciviru
hcv
myxoviru
influenza
rsv
infect
new
compound
clinic
develop
preclin
evalu
half
target
hiv
infect
yet
quit
number
import
viral
pathogen
ie
hpv
hcv
hemorrhag
fever
virus
remain
need
effect
andor
improv
antivir
therapi
present
forti
antivir
drug
formal
licens
clinic
treatment
viral
infect
mainli
use
treatment
infect
caus
human
immunodefici
viru
hiv
hepat
b
viru
hbv
herpesvirus
herp
simplex
viru
hsv
varicellazost
viru
vzv
cytomegaloviru
cmv
orthomyxovirus
influenza
paramyxovirus
respiratori
syncyti
viru
rsv
hepacivirus
hepat
c
viru
hcv
virus
demand
antivir
therapi
prompt
search
new
antivir
strategi
drug
direct
toward
either
molecular
target
approv
antivir
drug
target
newli
describ
antivir
compound
current
develop
target
hiv
hbv
hcv
target
hsv
vzv
cmv
addit
mani
import
viral
pathogen
medic
intervent
either
prophylact
therapeut
highli
need
among
dna
virus
papillomavirus
human
papilloma
viru
hpv
adenovirus
poxvirus
variola
vaccinia
monkeypox
herpesvirus
epsteinbarr
ebv
human
herpesviru
type
hhv
among
rna
virus
enterovirus
ie
coxsacki
b
echo
coronavirus
ie
sever
acut
respiratori
syndrom
sar
associ
coronaviru
flavivirus
ie
dengu
yellow
fever
rna
virus
associ
hemorrhag
fever
arenavirus
ie
lassa
fever
bunyavirus
ie
rift
valley
fever
crimeancongo
fever
filovirus
ie
ebola
marburg
describ
viral
famili
antivir
drug
formal
approv
ii
compound
clinic
develop
thu
may
consid
antivir
drug
candid
iii
compound
preclin
stage
develop
still
long
rout
ahead
could
qualifi
antivir
drug
tabl
figur
viru
famili
address
follow
parvo
polyoma
papilloma
adeno
herp
pox
picorna
flavi
corona
orthomyxo
paramyxo
arena
bunya
rhabdo
filo
reo
retrovirus
among
enterovirus
polio
hepat
effici
control
vaccin
polio
life
attenu
inactiv
kill
viru
vaccin
wherea
hepat
inactiv
viru
vaccin
avail
enterovirus
coxsacki
b
echovirus
rhinovirus
need
approach
chemotherapeut
agent
singl
antivir
drug
ever
licens
clinic
use
enteroor
rhinoviru
infect
extens
studi
potenti
enterovirus
pleconaril
compound
bind
hydrophob
pocket
beneath
canyon
floor
capsid
protein
picornavirus
therebi
freez
viral
capsid
prevent
dissoci
uncoat
viral
rna
genom
clinic
efficaci
pleconaril
evalu
experiment
induc
enteroviru
coxsacki
respiratori
infect
adult
volunt
compassion
basi
potenti
lifethreaten
enteroviru
infect
pleconaril
also
shown
reduc
durat
sever
picornavirusassoci
viral
respiratori
ill
adolesc
adult
pleconaril
would
also
shorten
cours
enterovir
mening
compar
placebo
recipi
albeit
modestli
patient
sever
diseas
prevent
andor
treatment
rhinoviru
infect
common
cold
inhibitor
human
rhinoviru
hrv
proteas
extens
investig
ruprintrivir
irrevers
proteas
inhibitor
upon
intranas
administr
human
volunt
appear
safe
well
toler
experiment
induc
rhinoviru
cold
healthi
volunt
ruprintrivir
prophylaxi
reduc
proport
subject
posit
viral
cultur
decreas
frequenc
cold
anoth
irrevers
inhibitor
hrv
proteas
refer
pyrrolidinyl
penteno
acid
ethyl
ester
compound
compound
offer
advantag
oral
bioavail
healthi
volunt
singl
oral
dose
compound
appear
safe
well
toler
although
compound
current
progress
toward
clinic
develop
despit
extens
research
effort
led
discoveri
mani
potent
antivir
agent
drug
today
approv
treatment
prevent
rhinovirusassoci
ill
sever
reason
consid
tri
understand
situat
major
individu
rhinovirusinduc
cold
mild
selflimit
alon
dictat
potenti
drug
must
safe
high
riskbenefit
ratio
agent
must
limit
side
effect
low
risk
resist
develop
furthermor
must
administ
low
frequenc
eg
less
three
time
day
date
agent
abl
achiev
criteria
demonstr
appropri
clinic
efficaci
great
need
antivir
treatment
often
sever
complic
coxsacki
b
viru
infect
myocard
may
lead
idiopath
dilat
cardiomyopathi
mice
coxsacki
virusinduc
myocard
inhibit
immunosuppress
agent
mycophenol
acid
mpa
mofetil
benefici
outcom
must
appar
result
immunosuppress
effect
mpa
inhibit
imp
dehydrogenas
henc
gtp
suppli
sinc
mpa
reduc
infecti
viru
titer
myocard
pronounc
inhibitori
effect
coxsacki
virusinduc
myocard
accompani
mark
reduct
viru
titer
heart
obtain
interferon
induc
poli
c
poli
c
u
also
known
ampligen
lesser
extent
pegyl
combin
inhibitor
viral
replic
ampligen
immunosuppress
mpa
mofetil
could
ideal
treatment
strategi
viral
myocard
whether
due
coxsacki
b
virus
implement
treatment
regimen
clinic
set
address
investig
whether
rna
interfer
rnai
protect
coxsacki
viru
infect
sever
coxsackieviru
small
interf
rna
sirna
target
distinct
region
viral
genom
evalu
effect
one
inhibit
viru
replic
target
viral
proteas
primordi
requir
effect
perfect
sequenc
match
central
region
target
shown
polioviru
viru
may
readili
escap
rna
interfer
rnai
uniqu
point
mutat
ie
result
g
u
mismatch
within
target
region
howev
emerg
resist
viru
could
prevent
use
pool
sirna
simultan
target
multipl
site
viral
genom
antivir
current
avail
treatment
alphaor
flaviviru
infect
although
live
viru
vaccin
routin
use
prophylaxi
yellow
fever
prospect
effect
therapi
flaviviru
infect
seem
encourag
antivir
compound
ribavirin
weak
activ
flavivirus
greater
hope
may
vest
interferon
interferon
induc
base
infect
hamster
murin
modoc
viru
experiment
flaviviru
enceph
model
develop
reminisc
japanes
enceph
viru
infect
human
relat
model
modoc
viru
scid
mice
whether
pegyl
interferon
induc
poli
c
ampligen
shown
significantli
delay
virusinduc
morbid
paralysi
mortal
due
progress
enceph
ribavirin
provid
benefici
effect
model
whether
given
alon
combin
interferon
recent
new
inhibitor
flaviviru
infect
identifi
highthroughput
screen
compound
librari
particular
triaryl
pyrazolin
phenylmethanon
found
inhibit
vitro
replic
number
flavivirus
ie
west
nile
dengu
yellow
fever
st
loui
enceph
well
virus
western
equin
enceph
viru
alphaviru
mous
hepat
viru
coronaviru
vesicular
stomat
viru
rhabdoviru
triaryl
pyrazolin
would
specif
target
viral
rna
synthesi
rna
interfer
rnai
demonstr
hepadna
picorna
hepaci
corona
myxoand
retrovirus
may
also
explor
antivir
approach
control
alphaand
flavivirus
exampl
level
vector
mosquito
rna
interfer
act
natur
antivir
respons
infect
anophel
gambia
alphaviru
onyongonyong
two
mosquitoborn
virus
semliki
forest
viru
sfv
dengu
viru
serotyp
shown
replic
mosquito
cell
could
specif
block
si
doublestrand
rna
indic
use
specif
sirna
may
inhibit
viru
replic
insect
host
thu
prevent
diseas
transmiss
current
approv
therapi
chronic
hepat
c
consist
pegyl
parenter
weekli
combin
ribavirin
oral
daili
treatment
regimen
associ
sustain
viral
respons
least
patient
infect
hcv
genotyp
patient
infect
anoth
genotyp
hcv
durat
treatment
week
longer
patient
infect
hcv
genotyp
may
reduc
week
patient
infect
anoth
genotyp
although
interferon
gener
act
immunomodulatori
agent
ie
treatment
hepat
b
ribavirin
antivir
agent
two
agent
use
combin
hepat
c
appear
act
way
around
interferon
appear
target
phosphoprotein
encod
nonstructur
gene
hcv
genom
thu
achiev
antivir
effect
wherea
ribavirin
akin
mpa
primarili
act
inhibitor
imp
dehydrogenas
thu
reduc
biosynthesi
gtp
ribavirin
recent
shown
modul
tcell
reactiv
hcv
ie
suppress
product
combin
peginterferon
ribavirin
also
advoc
therapi
hcv
infect
patient
hiv
coinfect
howev
forgotten
patient
treat
hiv
infect
azidothymidin
zidovudin
zdv
latter
may
antagon
ribavirin
therefor
reassur
note
ribavirin
mgday
administ
combin
peginterferon
significantli
affect
intracellular
phosphoryl
plasma
pharmacokinet
zdv
pyrimidin
dideoxynucleosid
hivhcvcoinfect
patient
addit
peginterferon
peginterferon
interferon
clinic
develop
eg
fuse
human
serum
albumin
allow
dose
interv
week
compar
one
week
peginterferon
consensu
interferon
ie
combin
ribavirin
shown
achiev
higher
sustain
respons
rate
patient
chronic
hepat
c
compar
standard
ribavirin
recent
novel
variant
gea
describ
would
better
inhibitori
activ
standard
hcv
replicon
system
due
potent
activ
jakstat
signal
pathway
combin
peginterferon
ribavirin
may
advantag
replac
viramidin
taribavirin
amidin
analogu
convert
mainli
hepatocyt
adenosin
deaminas
ribavirin
latter
reduc
uptak
therefor
lesser
toxic
red
blood
cell
compar
ribavirin
viramidin
would
give
less
anemia
compar
ribavirin
phase
iii
studi
viramidin
combin
peginterferon
compar
ribavirin
combin
peginterferon
eagerli
await
assess
one
choos
ribavirin
viramidin
take
account
durat
combin
interferon
plu
ribavirin
treatment
therewith
associ
side
effect
cost
partial
respons
observ
treatment
regimen
fierc
attempt
made
right
develop
select
antihcv
agent
target
specif
viral
protein
serin
proteas
rna
helicas
rna
replicas
rnadepend
rna
polymeras
also
hcv
protein
form
ion
channel
block
longalkylchain
iminosugar
deriv
consid
potenti
target
antivir
therapi
proofofprincipl
compound
target
proteas
could
reduc
plasma
concentr
hcv
rna
alreadi
deliv
biln
administ
oral
longer
day
patient
infect
hcv
genotyp
biln
ciluprevir
effici
largescal
synthet
procedur
describ
recent
abl
reduc
hcv
rna
level
log
patient
infect
hcv
genotyp
day
treatment
patient
infect
hcv
genotyp
prove
less
effect
appar
due
lower
affin
biln
hcv
proteas
genotyp
compar
genotyp
replac
five
residu
posit
could
account
reduc
sensit
genotyp
proteas
replac
residu
alon
combin
substitut
residu
posit
could
account
reduc
sensit
genotyp
appar
rigid
biln
confer
greater
potenc
genotyp
render
sensit
variat
near
bind
site
proteas
despit
robust
antivir
respons
observ
biln
genotyp
hcvinfect
individu
clinic
develop
compound
halt
cardio
toxic
issu
anim
anoth
proteas
inhibitor
differ
vitro
resist
profil
biln
telaprivir
substitut
either
valin
threonin
led
crossresist
biln
also
reduc
fit
replic
capac
transient
replicon
cell
system
major
biln
mutant
fulli
suscept
vice
versa
domin
mutant
remain
sensit
biln
thu
biln
must
elicit
resist
hcv
proteas
differ
mechan
mg
everi
hour
found
achiev
end
daytreat
main
reduct
hcv
rna
log
patient
receiv
show
log
declin
hcv
rna
patient
dose
viru
becam
undetect
day
dose
overal
preclin
profil
support
candidaci
novel
oral
therapi
hepat
c
combin
found
addit
synergist
reduc
hcv
rna
replicon
cell
combin
also
suppress
emerg
vitro
resist
mutat
replicon
cell
follow
promis
result
phase
clinic
trial
compound
progress
phase
ii
trial
evalu
combin
without
ribavirin
addit
acidbas
macrocycl
inhibitor
hcv
proteas
well
sch
mechanismbas
inhibitor
hcv
proteas
preclin
develop
fact
latter
found
act
synergist
suppress
hcv
replicon
synthesi
demonstr
good
oral
bioavail
rat
dog
advanc
clinic
trial
human
treatment
hcv
infect
sch
highest
dose
use
mg
three
time
daili
day
achiev
log
declin
viremia
sch
evalu
combin
pegyl
without
ribavirin
ongo
phase
ii
studi
hcv
proteas
inhibitor
sch
select
number
mutat
ie
mutat
confer
highest
level
resist
sch
also
led
greatest
reduct
fit
mutat
also
confer
high
level
resist
sch
novel
ketoamid
structur
relat
sch
inhibitor
proteas
novel
mutat
identifi
confer
moder
resist
unlik
minim
impact
enzymat
activ
significantli
reduc
enzymat
activ
polyprotein
process
replic
fit
howev
three
separ
secondsit
mutat
capabl
partial
revers
fit
without
significantli
reduc
resist
proteas
inhibitor
addit
proteas
rna
replicas
also
perceiv
attract
target
develop
hcv
inhibitor
highli
potent
select
antivir
agent
ie
target
viral
rna
replicas
describ
inhibit
replic
bovin
viral
diarrhoea
viru
bvdv
pestiviru
could
consid
surrog
viru
hcv
recent
describ
two
novel
seri
compound
prototyp
methyl
act
nonnucleosid
rna
replicas
inhibitor
nnrri
effect
highli
potent
select
inhibit
replic
bvdv
bpip
class
compound
new
congen
deriv
act
equal
effici
hcv
replic
futur
treatment
strategi
hcv
infect
nnrri
may
like
combin
nucleosid
rna
replicas
inhibitor
nrri
analog
strategi
follow
treatment
hiv
infect
nrti
combin
nnrti
see
infra
sole
nrri
alreadi
proceed
phase
iii
clinic
trial
therapi
hepat
c
ovalin
ester
cmethylcytidin
valopicitabin
administ
oral
rout
show
enhanc
antivir
efficaci
combin
peginterferon
valopicitabin
current
phase
ii
combin
trial
pegyl
would
wise
add
ribavirin
combin
shown
ribavirin
antagon
vitro
antihcv
activ
cmethylcytidin
activ
compound
valopicitabin
hcv
replicon
resist
cmethylcytidin
cmethylpurin
nucleosid
readili
isol
vitro
resist
result
mutat
gene
consequ
mutat
cmethyl
ctp
longer
incorpor
initi
step
rna
synthesi
addit
presenc
mutat
also
compromis
incorpor
natur
nucleotid
may
translat
decreas
viral
fit
addit
cmethylcytidin
sever
ribonucleosid
analogu
nrri
report
inhibit
hcv
replic
review
cmethyladenosin
cmethyladenosin
cmethylguanosin
cmethylcytidin
azidocytidin
specif
inhibitor
hcv
antibvdv
activ
fact
show
reduc
activ
rdrp
mutant
resist
cmethyl
nucleosid
suggest
inhibitor
hcv
rna
synthesi
contrast
azidocytidin
show
crossresist
cmethylcytidin
thu
mutat
confer
resist
vitro
studi
map
resist
amino
acid
substitut
polymeras
aforement
nucleosid
analogu
principl
nonoblig
chaintermin
nucleosid
analogu
would
seem
interest
prepar
evalu
correspond
obligatori
chaintermin
deoxyribonucleosid
analogu
antihcv
activ
recent
done
cmethylcytidin
cmethyluridin
modifi
posit
newli
synthes
compound
quot
antivir
inact
hcv
figur
among
virus
evalu
suscept
compound
new
class
hcv
rna
replicas
inhibitor
repres
diketo
acid
dka
one
activ
dka
dka
compound
compound
reminisc
dka
type
hiv
integras
inhibitor
see
infra
assum
inhibit
hcv
polymer
activ
via
chelat
activ
site
mg
ion
certain
sens
may
consid
pyrophosph
mimic
thu
act
productlik
inhibitor
polymeras
reaction
recent
year
pleiad
nnrri
describ
act
similar
alloster
fashion
hcv
rna
replicas
nnrti
respect
hiv
revers
transcripas
benzimidazolebas
deriv
ie
benzimidazol
deriv
indolenacetamid
deriv
deriv
phenylalanin
deriv
thiophen
acid
deriv
dihydropyranon
deriv
tetrahydropyranoindolyl
acet
acid
deriv
renantiom
racem
mixtur
benzothiadiazin
alloster
bind
site
compound
alreadi
identifi
crystallograph
studi
correspond
narrow
cleft
protein
surfac
thumb
domain
enzym
catalyt
center
curious
nnrri
activ
hcv
polymeras
contain
besid
larg
hydrophob
region
carboxyl
acid
group
similar
motif
allow
hydrogen
bond
main
chain
amid
nitrogen
atom
ie
ser
tyr
demonstr
phenylalanin
deriv
indolenacetamid
deriv
suggest
may
displac
part
fingertip
loop
anchor
finger
domain
thumb
domain
use
thiophen
type
inhibitor
report
inhibitor
soak
crystal
form
adopt
close
conform
believ
activ
form
form
ii
adopt
open
conform
thu
inact
form
resist
mutat
emerg
benzimidazol
relat
compound
found
three
amino
acid
posit
thumb
domain
mutat
posit
confer
differ
level
resist
decreas
order
mutat
confer
resist
hcv
rna
replicas
ie
proteas
ie
identifi
mutat
confer
high
level
resist
biln
respect
howev
mutant
remain
suscept
nrri
class
nnrri
well
interferon
addit
dualli
biln
resist
mutant
display
significantli
reduc
replic
abil
compar
wildtyp
find
support
rational
drug
combin
therapi
hcv
infect
recent
review
sever
approach
includ
ribozym
antisens
oligonucleotid
rna
interfer
rnai
base
short
interf
si
rna
could
envisag
target
hcv
genom
isi
antisens
oligonucleotid
complementari
intern
ribosom
entri
site
ire
phase
clinic
trial
gave
transient
hcv
reduct
log
patient
alt
alanyl
transaminas
flare
patient
short
interf
si
rna
aim
posttranscript
gene
silenc
may
consid
attract
approach
curtail
hcv
infect
sirna
approach
proven
efficaci
vivo
suppress
sar
coronaviru
infect
influenza
viru
infect
monkey
mice
respect
screen
variou
market
compound
arsen
trioxid
emerg
potent
hcv
inhibitor
similarli
sodium
stiboglucon
ssg
along
sever
antimoni
compound
includ
sb
sbcl
found
exert
potent
antihcv
activ
concentr
affect
cell
viabil
ssg
combin
two
drug
act
synergist
suppress
hcv
replic
variou
cellular
target
may
also
envisag
interfer
hcv
infect
sens
inhibitor
deoxynojirimycin
shown
disturb
morphogenesi
hcvlike
particl
may
eventu
use
fight
hcv
infect
part
drug
combin
protocol
anoth
cellular
target
chemotherapeut
intervent
cyclophilin
b
cyp
b
critic
effici
replic
hcv
genom
cyp
b
function
regul
hcv
rna
polymeras
cyclosporin
interact
cyp
b
inhibit
hcv
replic
vitro
recent
demonstr
nonimmunosuppress
cyclosporin
even
potent
inhibitor
hcv
replic
prove
also
addit
slightli
synergist
combin
concentr
abl
clear
cell
hcv
replicon
within
three
four
passag
wherea
treatment
cyclosporin
concentr
seven
consecut
passag
result
clearanc
hcv
replicon
may
form
attract
new
option
therapi
hcv
infect
particularli
hcvhiv
coinfect
patient
clinic
studi
recent
initi
hcv
sever
protein
encod
sar
coronaviru
could
consid
target
chemotherapeut
intervent
ie
spike
protein
main
proteas
ntpasehelicas
rnadepend
rna
polymeras
rna
replicas
possibl
viral
cellular
proteinmedi
process
sar
coronaviru
protein
mediat
infect
permiss
cell
interact
receptor
angiotensinconvert
enzym
ace
monoclon
antibodi
domain
found
neutral
viru
block
associ
receptor
ace
also
fusion
sar
coronaviru
cell
could
consid
attract
target
extent
fusion
process
bear
resembl
fusogen
mechan
hiv
ie
regard
heptad
repeat
interact
sixhelix
bundl
format
might
feasibl
develop
sar
coronaviru
inhibitor
analog
hiv
fusion
inhibitor
enfuvirtid
follow
receptor
bind
induc
conform
chang
spike
glycoprotein
third
step
would
involv
viral
entri
process
name
cathepsin
l
proteolysi
within
endosom
cathepsinlspecif
inhibitor
mdl
also
known
calpain
inhibitor
iii
zvalph
cho
time
inhibit
cathepsinl
activ
proteinmedi
infect
ic
nm
respect
addit
calpain
inhibitor
iii
calpain
inhibitor
describ
inhibitor
sar
coronaviru
replic
select
select
index
calpain
inhibitor
vi
cho
crystal
structur
sar
coronaviru
proteas
reveal
offer
solid
basi
ration
drug
design
sar
proteas
inhibitor
potenti
target
ntpasehelicas
rna
replicas
rnadepend
rna
polymeras
structur
basi
still
delin
number
peptidomimet
compound
aziridinyl
peptid
ketoglutamin
analogu
chymotrypsinlik
proteas
inhibitor
peptid
anilid
report
inhibitor
sar
coronaviru
main
proteas
niclosamid
anilid
k
ic
prove
potent
competit
inhibitor
case
proteas
inhibitor
shown
inhibit
sar
coronaviru
proteas
activ
viru
replic
cell
cultur
exampl
pheph
dipeptid
inhibitor
found
inhibit
proteas
ic
inhibit
viru
replic
vero
cell
ec
toxic
host
cell
concentr
select
index
recent
describ
potent
sar
coronaviru
proteas
inhibitor
k
nm
reduc
viru
product
cell
cultur
log
concentr
octapeptid
specif
design
sar
coronaviru
main
proteas
name
avlqsgfr
report
inhibit
sar
coronaviru
replic
vero
cell
ec
cytotox
thu
establish
select
index
whether
highli
select
antivir
effect
actual
mediat
inhibit
sar
coronaviru
main
proteas
ascertain
studi
sar
coronaviru
ntpasehelicas
consid
potenti
target
develop
antisar
agent
bananin
three
deriv
iodobananin
vanillinbananin
eubananin
shown
inhibit
atpas
helicas
activ
sar
coronaviru
ntpasehelicas
ic
valu
atpas
activ
rang
bananin
also
found
inhibit
sarscov
replic
fetal
rhesu
kidney
cell
ec
less
cc
thu
exhibit
select
index
whether
antivir
effect
obtain
cell
cultur
causal
link
inhibit
ntpasehelicas
ascertain
sar
coronaviru
rnadepend
rna
polymeras
rdrp
pivot
role
viral
replic
repres
anoth
potenti
target
antisar
therapi
enzym
contain
hydrophob
pocket
nonnucleosid
inhibitor
similar
proven
effect
hcv
polymeras
revers
transcriptas
fact
nonnucleosid
revers
transcriptas
inhibitor
shown
evid
inhibitori
effect
sar
coronaviru
rdrp
activ
present
nucleosid
analogu
recogn
specif
inhibitor
sar
coronaviru
rdrp
n
hydroxycytidin
accredit
antihcv
antisar
coronaviru
effect
sar
coronaviru
prove
activ
ec
select
index
whether
antivir
effect
mediat
inhibit
viral
rdrp
ascertain
howev
wide
varieti
old
new
compound
report
inhibit
vitro
replic
sar
coronaviru
rel
high
concentr
shortag
small
molecul
inhibit
replic
sar
viru
within
higher
concentr
rang
whether
molecul
would
abl
prevent
suppress
sar
vivo
remain
determin
typic
exampl
miscellan
compound
often
illdefin
mode
action
select
index
report
inhibit
sar
coronaviru
replic
valinomycin
glycyrrhizin
chloroquin
niclosamid
nelfinavir
short
interf
si
rna
develop
target
replicas
spike
gene
sar
coronaviru
genom
therebi
silenc
express
cell
cultur
potent
sirna
inhibitor
sar
coronaviru
vitro
ie
sirna
duplex
forward
sequenc
forward
sequenc
target
sar
coronaviru
genom
proteinand
nonstructur
region
respect
evalu
efficaci
rhesu
macaqu
sar
model
found
provid
relief
sar
coronaviru
infectioninduc
fever
diminish
sarscov
level
reduc
acut
diffus
alveolar
damag
studi
sirna
prophylact
therapeut
regimen
sar
coronaviru
seem
warrant
shortli
sar
coronaviru
identifi
caus
agent
sar
interferon
shown
inhibit
replic
sar
coronaviru
cell
cultur
vitro
potent
either
observ
subsequ
confirm
extend
sever
studi
conjunct
found
synergist
inhibit
replic
sar
coronaviru
vero
cell
prophylact
rather
therapeut
agent
interferon
may
highest
util
prophylaxi
earli
postexposur
manag
sar
pegyl
shown
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
attend
pulmonari
damag
cynomolg
macaqu
infect
experiment
sar
coronaviru
pegyl
commerci
avail
treatment
hepat
c
gener
use
combin
ribavirin
hepat
b
pegyl
well
commerci
avail
interferon
etc
could
consid
prevent
andor
earli
postexposur
treatment
sar
reemerg
mani
year
amantadin
rimantadin
use
prophylaxi
therapi
influenza
viru
infect
never
gain
wide
accept
primarili
risk
rapid
emerg
drugresist
viru
mutant
compound
interact
specif
matrix
protein
function
hydrogen
ion
h
channel
help
decapsid
uncoat
influenza
viru
particl
influenza
virus
harbor
amantadineresist
mutat
virul
wildtyp
viru
strain
readili
transmit
antivir
pressur
clinic
set
recent
year
neuraminidas
inhibitor
zanamivir
oseltamivir
becom
avail
therapi
andor
prophylaxi
influenza
b
viru
infect
influenza
adopt
uniqu
replic
strategi
use
one
surfac
glycoprotein
hemagglutinin
h
bind
target
cell
receptor
contain
termin
sialic
acid
nacetylneuramin
acid
nana
anoth
surfac
glycoprotein
neuraminidas
n
cleav
termin
sialic
acid
thu
allow
viru
particl
leav
cell
viral
replic
cycl
complet
neuraminidas
inhibitor
block
releas
progeni
viru
particl
virusinfect
cell
thu
prevent
viru
spread
host
cell
use
therapeut
neuraminidas
inhibitor
lead
reduct
ill
day
reduct
viru
transmiss
household
healthcar
contact
reduct
frequenc
sever
complic
sinus
bronchiti
diminish
use
antibiot
use
prophylact
neuraminidas
inhibitor
significantli
reduc
number
new
influenza
case
although
resist
human
influenza
virus
neuraminidas
inhibitor
develop
evid
natur
occur
resist
either
zanamivir
oseltamivir
zanamivir
oseltamivir
effect
influenza
b
among
influenza
prevail
variant
h
n
h
n
also
avian
flu
h
n
zanamivir
must
taken
oral
inhal
particular
oseltamivir
conveni
administ
oral
capsul
stockpil
affront
potenti
influenza
pandem
futur
increas
threat
avian
flu
h
n
need
suffici
suppli
neuraminidas
inhibitor
oseltamivir
zanamivir
becom
extrem
urgent
comparison
neuraminidas
inhibitor
exist
influenza
vaccin
like
limit
valu
newli
emerg
influenza
viru
strain
follow
zanamivir
oseltamivir
similar
structurebas
neuraminidas
inhibitor
develop
cyclopentan
deriv
peramivir
pyrrolidin
novel
neuraminidas
inhibitor
may
consid
potenti
drug
candid
amen
optim
lead
develop
yet
newer
compound
improv
activ
bioavail
andor
resist
profil
fact
peramivir
prove
effect
panel
five
zanamivirresist
six
oseltamivirresist
b
influenza
viru
strain
oseltamivir
resist
clinic
isol
human
influenza
associ
mutat
posit
neuraminidas
recent
resist
avian
influenza
oseltamivir
shown
caus
mutat
variant
still
appear
sensit
zanamivir
promin
among
neuraminidas
inhibitorresist
influenza
viru
mutat
yet
demonstr
wherea
mutat
associ
compromis
viru
growth
transmiss
growth
transmiss
variant
compar
wildtyp
viru
emerg
antivir
drug
resist
oseltamivir
treatment
associ
clinic
failur
immunocompromis
host
influenza
patient
highlight
need
altern
therapi
use
antivir
combin
concept
use
two
antivir
enhanc
antivir
effect
perhap
reduc
resist
emerg
decad
old
antivir
agent
besid
amantadin
rimantadin
neuraminidas
inhibitor
may
consid
potenti
prevent
andor
therapi
influenza
viru
infect
includ
avian
influenza
ribavirin
sinc
long
recogn
broadspectrum
antivir
agent
particular
activ
orthoand
paramyxovirus
earlier
observ
point
lack
oral
ribavirin
g
daili
natur
occur
influenza
viru
infect
intraven
ribavirin
mgkghour
hour
follow
mgkghour
day
may
worth
explor
therapeut
strategi
seriou
influenza
parainfluenza
viru
infect
recent
viramidin
carboxamidin
analogu
ribavirin
shown
similar
efficaci
ribavirin
influenza
viru
infect
consid
lesser
toxic
viramidin
may
warrant
evalu
possibl
therapi
influenza
includ
yet
recent
describ
compound
specif
activ
influenza
b
c
virus
carboxamid
flutimid
would
target
viral
polymeras
capdepend
endonucleas
respect
fact
polymeras
pa
complex
contribut
high
virul
avian
influenza
consid
attract
target
novel
antiinfluenza
viru
drug
develop
approach
curtail
potenti
influenza
viru
epidem
includ
carbohydratebind
molecul
defens
retrocyclin
inhibit
viral
fusion
entri
crosslink
membran
glycoprotein
shown
inhibit
influenza
viru
infect
well
tand
mtropic
viru
infect
furthermor
shown
sever
viru
infect
ie
hcv
infect
sar
coronaviru
infect
short
interf
rna
sirna
specif
conserv
influenza
viru
gene
may
also
expect
fact
demonstr
protect
anim
highli
pathogen
avian
influenza
virus
paramyxovirus
parainfluenza
type
receiv
littl
attent
either
prevent
cur
viewpoint
mump
measl
like
rubelliviru
rubella
consid
suffici
contain
vaccin
although
despit
exist
vaccin
half
million
death
per
year
result
measl
viru
prompt
search
fusion
inhibitor
block
measl
viru
entri
make
rsv
respiratori
syncyti
viru
hmpv
human
metapneumoviru
well
nipah
paramyxovirus
greatest
need
antivir
therapi
rsv
approv
antivir
therapi
aerosol
administr
ribavirin
practic
howev
ribavirin
rare
use
owe
technic
burden
deliveri
aerosol
given
circumst
rsv
bronchopneumon
young
infant
recent
intraven
ribavirin
togeth
oral
corticosteroid
prove
safe
costeffect
treatment
rsv
infect
lung
transplant
rsv
repres
risk
factor
bronchiol
obliteran
syndrom
major
limit
factor
longterm
surviv
lung
transplant
given
high
incid
rsv
infect
often
diagnos
influenza
high
yet
unmet
medic
need
appropri
therapi
prophylaxi
rsv
infect
hold
hmpv
infect
usual
occur
winter
season
rsv
mainli
young
children
elderli
peopl
immunocompromis
individu
ribavirin
certainli
hold
promis
treatment
hmpv
infect
recent
demonstr
mous
model
hmpv
mention
hcv
short
interf
rna
sirna
may
also
applic
properli
design
administ
intranas
treatment
respiratori
viru
infect
use
rna
interfer
rnai
approach
bitko
et
al
demonstr
respiratori
syncyti
viru
parainfluenza
viru
infect
individu
joint
could
specif
prevent
inhibit
sirna
instil
intranas
mous
without
transfect
reagent
case
measl
howev
rnai
approach
may
either
prevent
enhanc
viral
transcript
depend
target
mrna
nucleocapsid
n
phosphoprotein
p
polymeras
l
mrna
versu
matrix
mrna
avian
metapneumoviru
one
major
caus
respiratori
infect
poultri
sirna
specif
toward
phosphoprotein
p
led
mark
inhibit
viru
replic
recent
number
small
molecul
ie
formerli
known
although
structur
dissimilar
shown
fit
small
hydrophob
caviti
inner
core
rsv
fusion
f
protein
therebi
interact
heptad
repeat
domain
inhibit
rsv
fusion
although
therapeut
potenti
compound
treatment
rsv
infect
present
unclear
doubt
explor
mechan
interact
inhibitor
f
protein
facilit
design
new
rsv
fusion
inhibitor
cotton
rat
treatment
small
droplet
aerosol
min
min
significantli
reduc
mean
lung
viru
titer
found
potent
inhibitor
rsv
replic
vitro
exhibit
excel
potenc
multipl
laboratori
clinic
isol
b
rsv
averag
ec
nm
inhibit
fusion
viral
cellular
lipid
membran
earli
viru
entri
stage
latestag
syncytium
format
shown
oral
activ
rsv
balbc
mice
cotton
rat
even
administ
singl
oral
dose
hour
prior
intranas
rsv
inocul
could
consid
prototyp
smallmolecularweight
inhibitor
target
format
six
helic
coiledcoil
bundl
prelud
viruscel
fusion
rsv
also
hiv
fact
start
new
watersolubl
ie
carboxyl
acidsubstitut
deriv
synthes
potent
vitro
vivo
activ
rsv
peptid
contain
multipl
copi
altern
sequenc
termin
heptal
repeat
fprotein
design
inhibit
fproteinmedi
fusion
mbx
docosyloxymethyl
sodiumoxysulfonyl
onat
hand
inhibit
rsv
attach
cell
target
gprotein
rsv
attachmentfus
inhibitor
target
either
gor
fprotein
despit
mark
vitro
potenc
vivo
efficaci
cotton
rat
model
made
much
progress
clinic
set
part
poor
pharmacokinet
properti
therefor
new
rsv
inhibitor
act
target
distinct
attachmentfus
process
search
one
target
viral
nucleocapsid
n
protein
appear
target
ie
compound
enter
phase
ii
clinic
trial
accord
data
yet
made
avail
anoth
target
protein
worth
pursu
potenti
antirsv
agent
rnadepend
rna
polymeras
lprotein
identifi
point
attack
whether
compound
compound
potenti
therapi
andor
prophylaxi
rsv
infect
remain
evalu
although
human
parainfluenza
virus
import
respiratori
tract
pathogen
especi
children
receiv
littl
attent
either
prophylact
vaccin
therapeut
viewpoint
yet
contain
uniqu
target
major
surfac
glycoprotein
hemagglutininneuraminidas
hn
serv
time
cell
attach
viru
spread
hn
inhibitor
bcx
bcx
found
inhibit
function
block
infect
parainfluenza
virus
vitro
vivo
compound
may
limit
parainfluenza
viru
infect
human
compound
may
pursu
activ
parainfluenza
virus
rsv
well
influenza
virus
includ
flavonoid
uncinosid
polyoxotungst
diffaeoylquin
acid
isol
ethnobotan
ldeflexicalyx
arenavirus
known
five
associ
viral
hemorrhag
fever
lassa
junin
machupo
guanarito
sabia
ribavirin
proven
effect
postexposur
prophylaxi
therapi
experiment
arenaviru
infect
anim
model
anecdot
report
suggest
might
also
effect
treatment
arenaviru
infect
ie
machupo
sabia
human
convinc
evid
clinic
efficaci
obtain
case
lassa
fever
found
reduc
casefat
rate
irrespect
time
point
ill
treatment
start
equal
signific
prospect
doubleblind
placebocontrol
clinic
trial
intraven
ribavirin
therapi
shown
reduc
mortal
due
hantaan
infect
hfr
hemorrhag
fever
renal
syndrom
surpris
rna
bunyavirus
particular
hantavirus
among
sensit
rna
virus
ribavirin
vitro
bunyavirus
one
fear
highli
infecti
easili
transmit
human
associ
casefat
rate
approxim
crimeancongo
hemorrhag
fever
viru
bunyavirus
sensit
ribavirin
also
demonstr
experiment
anim
model
also
interferon
interferon
induc
prove
effect
treatment
experiment
bunyaviru
infect
likewis
consid
treatment
arenaviru
infect
warrant
efficaci
therapi
pichind
viru
infect
hamster
rhabdovirus
rabi
almost
invari
fatal
control
measur
taken
contain
repeat
inject
specif
immunoglobulin
andor
inactiv
kill
rabi
vaccin
soon
possibl
infect
filoviru
infect
ebola
marburg
vaccin
yet
avail
specif
immunoglobulin
may
limit
valu
treatment
filoviru
infect
indic
experiment
find
rhesu
macaqu
infect
ebola
zair
viru
antivir
drug
current
clinic
use
includ
ribavirin
provid
meaning
protect
filovirus
vivo
possibl
therapeut
strategi
may
base
use
sadenosylhomocystein
sah
hydrolas
inhibitor
sah
hydrolas
inhibitor
interfer
sadenosylmethionin
sam
depend
methyl
reaction
particularli
involv
cap
viral
mrna
virus
rhabdoviru
vsv
vesicular
stomat
viru
heavili
reli
mrna
cap
particularli
sensit
inhibit
sah
hydrolas
inhibitor
includ
biochem
filoand
rhabdovirus
quit
similar
replic
machineri
requir
cap
mrna
sah
hydrolas
inhibitor
may
logic
expect
effect
treatment
ebola
viru
infect
fact
administ
singl
dose
mgkg
found
protect
mice
lethal
infect
ebola
viru
zair
strain
protect
effect
accompani
proba
bli
mediat
product
high
concentr
interferon
ebola
virusinfect
mice
hypothes
block
cap
nascent
rna
viral
strand
henc
matur
toward
mrna
stimul
format
doublestrand
rna
complex
sinc
long
known
excel
induc
interferon
like
sah
hydrolas
imp
inosin
monophosph
dehydrogenas
anoth
cellular
enzym
may
envisag
target
antivir
agent
imp
dehydrogenas
crucial
enzym
involv
biosynthesi
gtp
although
ribavirin
may
act
distinct
virus
distinct
mechan
ie
imp
dehydrogenas
inhibit
immunomodulatori
effect
rna
cap
interfer
polymeras
hibit
lethal
mutagenesi
predomin
mechan
ribavirin
exert
antivir
activ
vitro
flavivirus
paramyxovirus
mediat
inhibit
imp
dehydrogenas
recent
new
class
compound
phosphorodiamid
morpholino
oligom
pmo
conjug
argininerich
cellpenetr
peptid
ppmo
design
base
pair
translat
start
region
ebolaviru
positivesens
rna
report
inhibit
ebolaviru
replic
protect
mice
lethal
ebolaviru
infect
similarli
sirna
target
ebola
viru
zair
polymeras
l
gene
deliv
use
snalp
stabl
nucleic
acidlipid
particl
found
complet
protect
guinea
pig
death
administ
shortli
ebola
viru
infect
reovirus
rotaviru
associ
viral
gastrointestin
infect
far
clinic
import
pathogen
sever
attempt
still
made
develop
effect
vaccin
rotaviru
infect
current
treatment
rotaviru
diarrhoea
mainli
base
administr
fluid
prevent
dehydr
seriou
attempt
develop
antivir
drug
diseas
although
noteworthi
replic
reo
rota
virus
exquisit
sensit
sah
hydrolas
inhibitor
also
small
interf
rna
sirna
correspond
gene
shown
effici
inhibit
synthesi
protein
reduc
yield
viral
progeni
virusinfect
cell
forti
compound
regist
antivir
drug
least
half
use
treat
hiv
infect
even
greater
number
compound
clinic
preclin
develop
mani
target
hiv
virus
taken
togeth
impli
hiv
sinc
advent
remain
main
stay
antivir
drug
develop
antivir
agent
guid
antihiv
agent
exampl
divid
roughli
five
categori
nucleosid
analogu
ii
nucleotid
analogu
acycl
nucleosid
phosphon
iii
nonnucleosid
analogu
iv
proteas
inhibitor
v
viruscel
fusion
inhibitor
molecular
target
ii
viral
dna
polymeras
whether
dnadepend
case
herpesvirus
rnadepend
case
hiv
hbv
iii
rnadepend
dna
polymeras
revers
transcriptas
associ
hiv
rnadepend
rna
polymeras
rna
replicas
associ
hcv
iv
proteas
associ
hiv
hcv
v
fusion
process
hiv
potenti
virus
sar
coronaviru
rsv
antivir
agent
may
also
exert
antivir
effect
interact
cellular
target
imp
dehydrogenas
ribavirin
sah
hydrolas
latter
enzym
essenti
viral
rna
synthesi
suppli
gtp
viral
mrna
matur
cap
respect
final
interferon
gener
provid
pegyl
form
may
advoc
therapi
viral
infect
actual
hbv
hcv
prospect
coxsacki
b
sar
yet
suffici
curb
therapeut
measur
